Viela Bio Revenue and Competitors
Estimated Revenue & Valuation
- Viela Bio's estimated annual revenue is currently $930k per year.
- Viela Bio received $250.0M in venture funding in March 2018.
- Viela Bio's estimated revenue per employee is $77,500
- Viela Bio's total funding is $357.3M.
Employee Data
- Viela Bio has 12 Employees.
- Viela Bio grew their employee count by -33% last year.
Viela Bio's People
Name | Title | Email/Phone |
---|---|---|
1 | Controller | Reveal Email/Phone |
2 | SVP, Head Commercial | Reveal Email/Phone |
3 | VP, Sales | Reveal Email/Phone |
4 | VP, Head Technical Operations | Reveal Email/Phone |
5 | VP Clinical Development | Reveal Email/Phone |
6 | Head Business Development and Operations | Reveal Email/Phone |
7 | Associate Director Quality Operations | Reveal Email/Phone |
8 | Director, Market Access & Value | Reveal Email/Phone |
9 | Senior Manager, Payroll and Equity | Reveal Email/Phone |
10 | Senior Manager, Compensation & Benefits | Reveal Email/Phone |
Viela Bio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $110.3M | 709 | -9% | N/A | N/A |
What Is Viela Bio?
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company's portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide. Viela Bio is located in Gaithersburg, Maryland. Learn more at www.vielabio.com
keywords:N/A$357.3M
Total Funding
12
Number of Employees
$930k
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Viela Bio News
... to witness significant growth over the forecast by 2028 | Alexion Pharmaceuticals Inc., Chugai Pharmaceutical Co., Ltd., Viela Bio, Inc.
... recently was vice president of clinical development at Horizon Therapeutics following its acquisition of Viela Bio, Inc. Prior to that,...
Most recently, he was Vice President, Clinical Development at Horizon Therapeutics following its acquisition of Viela Bio, Inc. At Horizon...
It's a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators' hands.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.9M | 12 | 0% | N/A |
#2 | $1.8M | 12 | -8% | N/A |
#3 | $1M | 12 | 9% | N/A |
#4 | $1M | 12 | -33% | N/A |
#5 | $2.1M | 12 | 0% | N/A |
Viela Bio Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2018-03-01 | $250.0M | Undisclosed | Boyu Capital | Article |